Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?

CURRENT OPINION IN ONCOLOGY(2019)

引用 34|浏览9
暂无评分
摘要
Purpose of review Despite the overall excellent survival rates in patients with cutaneous squamous cell carcinoma (cSCC), advanced cutaneous SCCs are associated with high patient morbidity and mortality. Therefore, important unmet clinical needs persist: identifying high risk patients and choosing optimal treatment approaches. Recent findings In recent years, a better understanding of the biology of cSCC and its clinical progression have led to improved staging systems and new promising treatments for advanced disease. Such treatments include PD1 inhibitors, such as cemiplimab, which was recently approved for the treatment of cutaneous SCC, and pembrolizumab whose efficacy in the treatment cSCC is still being investigated. Other treatments, such as epidermal growth factor receptor inhibitors have also been used in the treatment of cSCC with moderate success. Several clinical and histological risk factors are considered key in estimating the risk or recurrence or metastasis in cSCCs and, therefore, influence the appropriate treatment choice and patient monitoring. The present study reviews the current definition of advanced cSCC and discusses the new systemic approaches, including checkpoint inhibitors.
更多
查看译文
关键词
advanced squamous cell carcinoma,chemotherapy,epidermal growth factor receptor inhibitors,immune checkpoint inhibitors,radiation therapy,risk factors,staging
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要